This is the current release of the guideline.

All clinical practice guidelines from the American Academy of Pediatrics automatically expire 5 years after publication unless reaffirmed, revised, or retired at or before that time.

The levels of evidence (A-D, X) and the strength of the recommendations (strong recommendation, recommendation, option, or no recommendation) are defined at the end of the "Major Recommendations" field.

Recommendation 1a

Clinicians should diagnose bronchiolitis and assess disease severity on the basis of history and physical examination. Clinicians should not routinely order laboratory and radiologic studies for diagnosis (recommendation: evidence level B).

Recommendation 1b

Clinicians should assess risk factors for severe disease such as age less than 12 weeks, a history of prematurity, underlying cardiopulmonary disease, or immunodeficiency when making  decisions about evaluation and management of children with bronchiolitis (recommendation: evidence level B).

Recommendation 2a

Bronchodilators should not be used routinely in the management of bronchiolitis (recommendation: evidence level B).

Recommendation 2b

A carefully monitored trial of alpha-adrenergic or beta-adrenergic medication is an option. Inhaled bronchodilators should be continued only if there is a documented positive clinical response to the trial using an objective means of evaluation (option: evidence level B).

Recommendation 3

Corticosteroid medications should not be used routinely in the management of bronchiolitis (recommendation: evidence level B).

Recommendation 4

Ribavirin should not be used routinely in children with bronchiolitis (recommendation: evidence level B).

Recommendation 5

Antibacterial medications should be used only in children with bronchiolitis who have specific indications of the coexistence of a bacterial infection. When present, bacterial infection should be treated in the same manner as in the absence of bronchiolitis (recommendation: evidence level B).

Recommendation 6a

Clinicians should assess hydration and ability to take fluids orally (strong recommendation: evidence level X).

Recommendation 6b

Chest physiotherapy should not be used routinely in the management of bronchiolitis (recommendation: evidence level B).

Recommendation 7a

Supplemental oxygen is indicated if oxyhemoglobin saturation (SpO₂) falls persistently below   90% in previously healthy infants. If the SpO₂ does persistently fall below 90%, adequate supplemental oxygen should be used to maintain SpO₂ at or above 90%. Oxygen may be discontinued if SpO₂ is at or above 90% and the infant is feeding well and has minimal respiratory distress (option: evidence level D).

Recommendation 7b

As the child's clinical course improves, continuous measurement of SpO₂ is not routinely needed (option: evidence level D).

Recommendation 7c

Infants with a known history of hemodynamically significant heart or lung disease and premature infants require close monitoring as the oxygen is being weaned (strong recommendation: evidence level B).

Recommendation 8a

Clinicians may administer palivizumab prophylaxis to selected infants and children with chronic lung disease (CLD)or a history of prematurity (less than 35 weeks' gestation) or with congenital heart disease (recommendation: evidence level A).

Recommendation 8b

When given, prophylaxis with palivizumab should be given in 5 monthly doses, usually beginning in November or December, at a dose of 15 mg/kg per dose administered intramuscularly (recommendation: evidence level C).

Recommendation 9a

Hand decontamination is the most important step in preventing nosocomial spread of respiratory syncytial virus (RSV). Hands should be decontaminated before and after direct contact with patients, after contact with inanimate objects in the direct vicinity of the patient, and after removing gloves (strong recommendation: evidence level B).

Recommendation 9b

Alcohol-based rubs are preferred for hand decontamination. An alternative is hand-washing with antimicrobial soap (recommendation: evidence level B).

Recommendation 9c

Clinicians should educate personnel and family members on hand sanitation (recommendation: evidence level C).

Recommendation 10a

Infants should not be exposed to passive smoking (strong recommendation: evidence level B).

Recommendation 10b

Breastfeeding is recommended to decrease a child's risk of having lower respiratory tract disease (LRTD) (recommendation: evidence level C).

Recommendation 11

Clinicians should inquire about use of complementary and alternative medicine (CAM) (option: evidence level D).

Definitions:

Evidence Based Grading Scale

A: Well designed randomized controlled trials (RCTs) or diagnostic studies on relevant populations

B: RCTs or diagnostic studies with minor limitations; overwhelming consistent evidence from observational studies

C: Observational studies (Case-control and cohort design)

D: Expert opinion, case reports, reasoning from first principles

X: Exceptional situations in which validating studies cannot be performed and there is a clear preponderance of benefit or harm

Strength of Recommendations

Strong recommendation: A strong recommendation in favor of a particular action is made when the anticipated benefits of the recommended intervention clearly exceed the harms (as a strong recommendation against an action is made when the anticipated harms clearly exceed the benefits) and the quality of the supporting evidence is excellent. In some clearly identified circumstances, strong recommendations may be made when high-quality evidence is impossible to obtain and the anticipated benefits strongly outweigh the harms.

Recommendation: A recommendation in favor of a particular action is made when the anticipated benefits exceed the harms but the quality of evidence is not as strong. Again, in some clearly identified circumstances, recommendations may be made when high quality evidence is impossible to obtain but the anticipated benefits outweigh the harms.

Option: Options define courses that may be taken when either the quality of evidence is suspect or carefully performed studies have shown little clear advantage to one approach over another.

No recommendation: No recommendation indicates that there is a lack of pertinent published evidence and that the anticipated balance of benefits and harms is presently unclear.

None provided

Evidence Profile 1a: Diagnosis

• Aggregate evidence quality: B; diagnostic studies with minor limitations and observational studies with consistent findings
• Benefit: cost saving, limitation of radiation and blood tests
• Harm: risk of misdiagnosis
• Benefits-harms assessment: preponderance of benefit over harm
• Policy level: recommendation

Evidence Profile 1b: Risk Factors

• Aggregate evidence quality: B; observational studies with consistent findings
• Benefit: improved care of patients with risk factors for severe disease
• Harm: increased costs, increased radiation and blood testing
• Benefits-harms assessment: preponderance of benefit over harm
• Policy level: recommendation

Evidence Profile 2a: Routine Use of Bronchodilators

• Aggregate evidence quality: B; randomized controlled trials (RCTs) with limitations
• Benefit: short-term improvement in clinical symptoms
• Harm: adverse effects, cost of medications, cost to administer
• Benefits-harms assessment: preponderance of harm over benefit
• Policy level: recommendation

Evidence Profile 2b: Trial of Bronchodilators

• Aggregate evidence quality: B; RCTs with limitations
• Benefit: some patients with significant symptomatic improvement
• Harm: adverse effects, cost of medications, cost to administer
• Benefits-harms assessment: preponderance of benefit over harm in select patients
• Policy level: option

Evidence Profile 3: Corticosteroids

• Aggregate evidence quality: B; randomized clinical trials with limitations
• Benefit: possibility that corticosteroid may be of some benefit
• Harm: exposure to unnecessary medication
• Benefits-harms assessment: preponderance of harm over benefit
• Policy level: recommendation

Evidence Profile 4: Ribavirin

• Aggregate evidence quality: B; RCTs with limitations and observational studies
• Benefit: some improvement in outcome
• Harm: cost, delivery method, potential health risks to caregivers
• Benefits-harms assessment: preponderance of harm over benefit
• Policy level: recommendation

Evidence Profile 5: Antibacterial Therapy

• Aggregate evidence quality: B; RCTs and observational studies with consistent results
• Benefit: appropriate treatment of bacterial infections, decreased exposure to unnecessary medications and their adverse effects when a bacterial infection is not present, decreased risk of development of resistant bacteria
• Harm: potential to not treat patient with bacterial infection
• Benefits-harms assessment: preponderance of benefit over harm
• Policy level: recommendation

Evidence Profile 6a: Fluids

• Aggregate evidence quality: evidence level X; validating studies cannot be performed
• Benefit: prevention of dehydration
• Harm: overhydration, especially if syndrome of inappropriate secretion of antidiuretic hormone (SIADH) is present
• Benefits-harms assessment: clear preponderance of benefit over harm
• Policy level: strong recommendation

Evidence Profile 6b: Chest Physiotherapy

• Aggregate evidence quality: B; RCTs with limitations
• Benefit: clearance of secretions, prevention of atelectasis
• Harm: stress to infant during procedure, cost of administering chest physiotherapy
• Benefits-harms assessment: preponderance of harm over benefit
• Policy level: recommendation

Evidence Profile 7a: Supplemental Oxygen

• Aggregate evidence quality: D; expert opinion and reasoning from first principles
• Benefit: use of supplemental oxygen only when beneficial, shorter hospitalization
• Harm: inadequate oxygenation
• Benefits-harms assessment: some benefit over harm
• Policy level: option

Evidence Profile 7b: Measurement of SpO2

• Aggregate evidence quality: D; expert opinion
• Benefit: shorter hospitalization
• Harm: inadequate oxygenation between measurements
• Benefits-harms assessment: some benefit over harm
• Policy level: option

Evidence Profile 7c: High-Risk Infants

• Aggregate evidence quality: B; observational studies with consistent findings
• Benefit: improved care of high-risk infants
• Harm: longer hospitalization, use of oxygen when not beneficial
• Benefits-harms assessment: preponderance of benefit over harm
• Policy level: Strong recommendation

Evidence Profile 8a: Palivizumab Prophylaxis

• Aggregate evidence quality: A; RCTs
• Benefit: prevention of morbidity and mortality in high-risk infants
• Harm: cost
• Benefits-harms assessment: preponderance of benefit over harm
• Policy level: recommendation

Evidence Profile 8b: Five-Dose Regimen

• Aggregate evidence quality: C; observational studies and expert opinion
• Benefit: decreased cost resulting from using minimal number of needed doses
• Harm: risk of illness from respiratory syncytial virus (RSV) outside the usual season
• Benefits-harms assessment: preponderance of benefit over harm
• Policy level: recommendation

Evidence Profile 9a: Hand Decontamination

• Aggregate evidence quality: B; observational studies with consistent findings
• Benefit: decreased spread of infection
• Harm: time
• Benefits-harms assessment: strong preponderance of benefit over harm
• Policy level: strong recommendation

Evidence Profile 9b: Alcohol-Based Rubs

• Aggregate evidence quality: B; observational studies with consistent findings
• Benefit: decreased spread of infection
• Harm: irritative effect of alcohol-based rubs
• Benefits-harms assessment: preponderance of benefit over harm
• Policy level: recommendation

Evidence Profile 9c: Education

• Aggregate evidence quality: C; observational studies
• Benefit: decreased spread of infection
• Harm: time, cost of gloves and gowns if used, barriers to parental contact with patient
• Benefits-harms assessment: preponderance of benefit over harm
• Policy level: recommendation

Evidence Profile 10a: Secondhand Smoke

• Aggregate evidence quality: B; observational studies with consistent findings
• Benefit: decreased risk of lower respiratory tract infection (LRTI)
• Harm: none
• Benefits-harms assessment: strong preponderance of benefit over harm
• Policy level: strong recommendation

Evidence Profile 10b: Breastfeeding

• Aggregate evidence quality: C; observational studies
• Benefit: improved immunity, decreased risk of LRTI, improved nutrition
• Harm: implied inadequacy of mothers who cannot or prefer to not breastfeed
• Benefits-harms assessment: preponderance of benefit over harm
• Policy level: recommendation

Evidence Profile 11: Asking About complimentary alternative medicine (CAM)

• Aggregate evidence quality: D; expert opinion
• Benefit: improved parent-physician communication, awareness of other, possibly harmful treatments being used
• Harm: time required for discussion, lack of knowledge about CAM by many pediatricians
• Benefits-harms assessment: some benefit over harm
• Policy level: option

Not applicable: The guideline was not adapted from another source.

2006 Oct

American Academy of Pediatrics - Medical Specialty Society

American Academy of Pediatrics

Subcommittee on Diagnosis and Management of Bronchiolitis

Subcommittee on the Diagnosis and Management of Bronchiolitis, 2004 to 2006: Allan S. Lieberthal, MD, Chairperson; Howard Bauchner, MD; Caroline B. Hall, MD; David W. Johnson, MD; Uma Kotagal, MD; Michael J. Light, MD (on the AstraZeneca and MedImmune speakers' bureaus; research grant from MedImmune); Wilbert Mason, MD (on the MedImmune speakers' bureau); H. Cody Meissner, MD; Kieran J. Phelan, MD; Joseph J. Zorc, MD

Liaisons: Mark A. Brown, MD (on the GlaxoSmithKline, AstraZeneca, and MedImmune speakers' bureaus) American Thoracic Society; Richard D. Clover, MD (continuing medical education presenter for institutions that received unrestricted educational grants from Sanofi Pasteur and Merck) American Academy of Family Physicians; Ian T. Nathanson, MD, American College of Chest Physicians; Matti Korppi, MD, European Respiratory Society

Consultants: Richard N. Shiffman, MD; Danette Stanko-Lopp, MA, MPH

Staff: Caryn Davidson, MA

All panel members reviewed the American Academy of Pediatrics (AAP) Policy on Conflict of Interest and Voluntary Disclosure and were given an opportunity to declare any potential conflicts.

This is the current release of the guideline.

All clinical practice guidelines from the American Academy of Pediatrics automatically expire 5 years after publication unless reaffirmed, revised, or retired at or before that time.

None available

This NGC summary was completed by ECRI on December 15, 2006. The information was verified by the guideline developer on December 22, 2006.

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions. Please contact the Permissions Editor, American Academy of Pediatrics (AAP), 141 Northwest Point Blvd, Elk Grove Village, IL 60007.